About Paclitero 260mg Injection
Paclitero 260mg Injection is an anticancer medication used to treat various cancers, including breast cancer, non-small cell lung cancer, ovarian cancer, and AIDS-related Kaposi's sarcoma. It works by interfering with the growth and division of cancer cells, helping to slow or stop their spread throughout the body. Depending on the type and stage of cancer, Paclitero 260mg Injection may be administered alone or in combination with other chemotherapy medicines to improve treatment outcomes. This medication is not recommended for patients with severe liver disease, uncontrolled infections, or significantly low white blood cell or platelet counts. It is also generally not suitable for children and adolescents under 18 years of age. Before starting treatment, patients should inform their healthcare provider about any history of heart disease or other underlying medical conditions, as close monitoring may be required. Serious allergic reactions can occur during administration, making medical supervision essential throughout treatment. Patients of reproductive age should use effective contraception during therapy and for at least six months after the final dose to prevent pregnancy-related risks. Additionally, because the formulation may contain alcohol, individuals with alcoholism or alcohol-related health conditions should discuss potential risks with their doctor before receiving Paclitero 260mg Injection.
Effective Anti-Cancer SolutionPaclitero 260mg Injection is specially formulated to combat ovarian cancer efficiently. The active ingredient, Paclitaxel, interferes with the cancer cell cycle, providing enhanced treatment outcomes when used as recommended by a healthcare professional.
Safe Storage for Maximum PotencyTo maintain Paclitero's effectiveness, it is vital to store this injectable medicine below 25C. Protecting the injection from excessive heat or direct sunlight helps in retaining its therapeutic properties until the expiration date in 2028.
Trusted Indian Origin and PackagingPaclitero is manufactured in India, rigorously adhering to international standards. Each box contains one sterile injection, allowing for ease of handling in clinical settings and supporting consistent dosing for effective patient care.
FAQ's of Paclitero 260mg Injection:
Q: How should Paclitero 260mg Injection be stored for optimal efficacy?
A: Paclitero 260mg Injection must be stored below 25C, away from direct sunlight and moisture, to ensure its stability and effectiveness until the expiration date.
Q: What is the primary benefit of Paclitero 260mg Injection in ovarian cancer treatment?
A: The main benefit lies in its ability to slow or halt ovarian cancer cell growth, thereby supporting disease control and improving patients' treatment prospects.
Q: When should Paclitero 260mg Injection be administered?
A: This injection is administered as part of a prescribed cancer treatment regimen, following a schedule recommended by a qualified healthcare provider.
Q: Where is Paclitero 260mg Injection produced, and is it suitable for international markets?
A: This injection is manufactured in India and is available globally through exporters, suppliers, and traders, meeting key pharmaceutical standards for international distribution.
Q: What is the process for using Paclitero 260mg Injection?
A: Paclitero is administered as an intravenous injection by a healthcare professional in a medical facility, ensuring accurate dosage and monitoring during treatment.
Q: Who should use Paclitero 260mg Injection?
A: Use is specifically recommended for patients diagnosed with ovarian cancer, under the supervision and guidance of an oncologist or authorized healthcare provider.